Developer docs
API playgroundTry for free, no card

Search company profiles

BASF Pharma

Full company profile

uuid000iccn

Namestring
BASF Pharma
Legal namestring
BASF SE
Websiteurl
pharma.basf.com
Company typeenum
Public
Founded yearint
1865
Descriptiontext

BASF Pharma Solutions is the pharmaceutical operating division of BASF SE, headquartered in Ludwigshafen, Germany, and produces innovative excipients and active pharmaceutical ingredients (APIs) for the global pharmaceutical industry. The company is described as the world's leading manufacturer of APIs such as ibuprofen and omega-3 fatty acids, and offers the world's largest portfolio of chemical raw materials for the pharmaceutical industry — over 700 products including building blocks, chiral auxiliaries, protective groups, reagents, solvents, and catalysts. Its offering is organized across five formulation platforms: Orals, Topicals, Parenterals, Solubilization, and Biopharma Ingredients. Notable proprietary products include Kolliphor poloxamers (including Kolliphor P 188 Bio for biopharma), Kollidon (Povidone, since 1928), Kollicoat film coatings, Soluplus for solid dispersions, Kollitab DC 87 L co-processed excipient, and Ibuprofen DC 85. The Bishop, Texas facility produces ibuprofen via a unique closed-system process requiring four steps versus six or seven at competitors.

The business model is anchored on direct enterprise sales via dedicated account managers, complemented by digital platforms (myBASFWorld for product information, ordering, and shipment tracking; ZoomLab for formulation support) and global manufacturing and distribution across the US, Europe, and Asia. Pricing is managed through account managers rather than publicly disclosed, and was raised by up to 20% on excipients and select APIs in March 2026 due to energy and raw material cost inflation. A new GMP Solution Center in Wyandotte, Michigan opened in June 2025 to support biopharma and small-molecule customers. The company cites a 52% market share among originator pharmaceutical companies and serves pharmaceutical manufacturers, API manufacturers, biopharmaceutical companies, and generic drug manufacturers as primary segments. The division is supported by education and thought leadership channels including the BASF Pharma Learning Center, the "10 Billion Reasons" podcast, webinars, and LinkedIn presence.

Short descriptiontext

BASF Pharma Solutions, a division of BASF SE, is the world's leading manufacturer of pharmaceutical excipients and APIs (including ibuprofen and omega-3 fatty acids), serving global originator, generic, and biopharmaceutical drug manufacturers across five formulation platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLudwigshafen, Germany
HQ citystring
Ludwigshafen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical excipients, active pharmaceutical ingredients, biopharma processing aids, drug formulation support, pharmaceutical raw materials
Industry1 code
PRIMARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Excipients & APIs
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Excipients and APIs
TypeOne Time License
Description

BASF Pharma Solutions generates revenue through the sale of pharmaceutical excipients, active pharmaceutical ingredients (APIs) including ibuprofen and omega-3 fatty acids, and chemical raw materials including building blocks, reagents, protective groups, solvents, and catalysts for pharmaceutical manufacturing.

pharmaceutical.basf.com
2Digital Services and Platform Access
TypeSubscription Recurring
Description

Revenue is supported by digital platform services including myBASFWorld for product information, ordering, and technical support, as well as consultation and technical service support for formulation development.

pharmaceutical.basf.com
3Contract Manufacturing and Custom Solutions
TypeProfessional Services
Description

BASF provides custom pharmaceutical development and manufacturing services with regulatory, quality, and technical service support for customers globally.

pharmaceutical.basf.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Product sales through account management
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is managed through dedicated account managers and is not publicly disclosed on the website. Customer inquiries are handled through contact forms and direct account manager engagement.

pharmaceutical.basf.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 12 records shown
1myBASFWorld
Description

Digital customer portal offering centralized product details, documentation access, ordering, and shipment tracking

pharmaceutical.basf.com
+11 more records
Core offering1 text field

BASF Pharma Solutions produces and supplies innovative pharmaceutical excipients and active pharmaceutical ingredients (APIs) including ibuprofen and omega-3 fatty acids for pharmaceutical and biopharmaceutical manufacturers worldwide. The division offers formulation expertise across five drug delivery platforms (Orals, Topicals, Parenterals, Solubilization, and Biopharma Ingredients) and supports customers with digital services including the myBASFWorld customer portal and ZoomLab virtual formulation tools.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Manufacturing process completed in only 4 steps versus 6-7 steps at competitors
+1 more record
Product overview1 text field

BASF Pharma Solutions is a comprehensive pharmaceutical portfolio comprising a wide range of excipients, APIs, and digital platforms. The core offerings include: Kolliphor® surfactants (poloxamers, HS 15, ELP) for solubilization and biologic formulations; Kollicoat® film coatings; Kollidon® (Povidone) polymers; Soluplus® for solubility enhancement; and Kollitab™ DC 87 L for tableting. BASF produces APIs including ibuprofen (with DC 85 direct compression grade) and omega-3 fatty acids. Digital services include myBASFWorld customer portal and ZoomLab® formulation tools. The portfolio serves multiple drug delivery platforms: Orals, Topicals, Parenterals, Solubilization, and Biopharma Ingredients, enabling customers to develop efficient, cost-effective, and reliable formulations across all major dosage forms.

Product and service14 records
1Active Pharmaceutical Ingredients (APIs)
CategoryActive Pharmaceutical Ingredients
Description

World-leading portfolio of APIs manufactured at FDA-audited, cGMP-certified facilities, including ibuprofen and omega-3 fatty acids supplied to pharmaceutical manufacturers globally.

2Ibuprofen API (including Ibuprofen DC 85)
CategoryAPI
Description

Ibuprofen API produced at the Bishop, Texas facility with four powder grades plus a direct-compressible grade (Ibuprofen DC 85) and fast-acting grades for tableting applications.

3Kolliphor® P 188 Bio
CategorySurfactant / Biopharma Excipient
Description

Flagship poloxamer-based surfactant used as a processing aid in biopharmaceutical manufacturing, positioned as the #1 alternative to polysorbate 20 and 80 in biologic drug formulations.

4Kolliphor® HS 15
CategorySurfactant / Parenterals Excipient
Description

Non-ionic solubilizer surfactant with a documented history of safe and effective use in approved and marketed parenteral drugs and biologic formulations.

5Kolliphor® ELP
CategorySurfactant / Parenterals Excipient
Description

Surfactant for parenteral and solubilization applications with an established safety profile in marketed drugs.

6Soluplus®
CategorySolubilization Polymer
Description

Novel solubilization polymer for solid dispersions that increases dissolution and inhibits recrystallization of poorly soluble drug candidates.

7Kollicoat® Film Coating Polymers
CategoryFilm Coating Excipient
Description

Film coating product line for oral dosage forms providing immediate release, controlled release, moisture protection, and taste masking solutions.

8Kollidon® (Povidone / PVP)
CategoryPolymer Excipient
Description

PVP-based polymers originated by BASF in 1928, used as binders, solubilizers and film formers in pharmaceutical formulations.

9Kollitab™ DC 87 L
CategoryCo-processed Tableting Excipient
Description

All-in-one co-processed excipient combining filler, binder, disintegrant and lubricant for direct compression tableting and continuous manufacturing processes.

10Kollisolv® PEG
CategoryPolyethylene Glycol Excipient
Description

Polyethylene glycol products for softgel fills, solubilization, and pharmaceutical formulations, including low-aldehyde variants for enhanced stability.

11myBASFWorld Digital Platform
CategoryDigital Customer Platform
Description

Centralized customer portal providing product detail pages with technical and regulatory information, always up-to-date documentation, self-service capabilities, transparent ordering and real-time shipment tracking for pharmaceutical customers.

12ZoomLab®
CategoryDigital Formulation Tool
Description

Virtual laboratory service providing formulation development support for pharmaceutical customers.

13Virtual Audit Service
CategoryAudit Service
Description

State-of-the-art virtual audit technology enabling authorized customers to conduct immersive 360-degree audits of the Bishop ibuprofen production facility remotely.

14Chemical Intermediates (Building Blocks, Chiral Auxiliaries, Protective Groups, Reagents, Solvents)
CategoryPharmaceutical Raw Materials
Description

BASF Intermediates portfolio of over 700 chemical raw materials for synthesis in the pharmaceutical industry, marketed under the world's largest portfolio of chemical intermediates products.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

BASF partnered with Mark Chandler of ACT Solutions Corp for a webinar on topical formulation development using self-emulsifying systems, leveraging ACT Solutions' expertise in stabilization techniques and co-processed excipients for pharmaceutical applications.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global supplier of pharma excipients, APIs, and bioprocessing ingredients to drug manufacturers and biopharma companies. Direct competitor in excipients, APIs, and biopharma raw materials with comparable distribution scale.

TypeDirect peer
Description

Specialty excipient supplier focused on film coatings, controlled-release polymers, and tableting excipients. Direct competitor to BASF's Kollicoat, Kollidon, and Kollitab product lines for oral solid dose formulations.

TypeDirect peer
Description

German specialty chemicals company with a dedicated Health Care business line producing pharmaceutical excipients, APIs, and drug delivery technologies. Most directly comparable peer given overlap in pharma polymers, APIs, and CDMO services for oral and parenteral formulations.

TypeDirect peer
Description

Specialty chemical company producing pharmaceutical excipients, controlled-release polymers, and tablet coatings. Direct competitor in oral solid dose excipients and solubilization polymers.

TypeBroad incumbent
Description

Diversified chemical manufacturer with pharmaceutical and personal care ingredients including cellulosics, silicones, and excipients. Broader portfolio than BASF Pharma but overlaps in pharma-grade polymers and intermediates.

TypeDirect peer
Description

Air Liquide subsidiary manufacturing specialty excipients and surfactants for pharmaceutical, cosmetic, and vaccine applications. Competes directly with BASF's Kolliphor surfactant portfolio in parenterals and biopharma.

7Merck KGaA (Life Science / MilliporeSigma)
TypeBroad incumbent
Description

Life Science division of Merck KGaA offers pharmaceutical raw materials, excipients, and bioprocessing ingredients alongside a much broader lab products portfolio. Comparable in excipients and bioprocessing segments but operates across a far wider scope.

TypeDirect peer
Description

Pharmaceutical Solutions division of IFF (formerly DuPont Nutrition & Biosciences) producing pharma excipients, controlled-release polymers, and bioavailability enhancers. Direct competitor in solubilization and oral excipients.

TypeDirect peer
Description

Specialty excipient manufacturer focused on cellulose-based binders, disintegrants, and fillers for oral solid dose formulations. Direct competitor in tableting excipients alongside BASF's Kollidon and Kollitab lines.

TypeDirect peer
Description

French global leader in starch-based pharmaceutical excipients and APIs, including cyclodextrates, polyols, and biopharma excipients. Competes directly with BASF Pharma Solutions in orals, biopharma, and solubilization platforms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BASF Pharma

Pharmaceutical Excipients & APIspharma.basf.com

BASF Pharma Solutions, a division of BASF SE, is the world's leading manufacturer of pharmaceutical excipients and APIs (including ibuprofen and omega-3 fatty acids), serving global originator, generic, and biopharmaceutical drug manufacturers across five formulation platforms.

What BASF Pharma does

BASF Pharma Solutions is the pharmaceutical operating division of BASF SE, headquartered in Ludwigshafen, Germany, and produces innovative excipients and active pharmaceutical ingredients (APIs) for the global pharmaceutical industry. The company is described as the world's leading manufacturer of APIs such as ibuprofen and omega-3 fatty acids, and offers the world's largest portfolio of chemical raw materials for the pharmaceutical industry — over 700 products including building blocks, chiral auxiliaries, protective groups, reagents, solvents, and catalysts. Its offering is organized across five formulation platforms: Orals, Topicals, Parenterals, Solubilization, and Biopharma Ingredients. Notable proprietary products include Kolliphor poloxamers (including Kolliphor P 188 Bio for biopharma), Kollidon (Povidone, since 1928), Kollicoat film coatings, Soluplus for solid dispersions, Kollitab DC 87 L co-processed excipient, and Ibuprofen DC 85. The Bishop, Texas facility produces ibuprofen via a unique closed-system process requiring four steps versus six or seven at competitors.

The business model is anchored on direct enterprise sales via dedicated account managers, complemented by digital platforms (myBASFWorld for product information, ordering, and shipment tracking; ZoomLab for formulation support) and global manufacturing and distribution across the US, Europe, and Asia. Pricing is managed through account managers rather than publicly disclosed, and was raised by up to 20% on excipients and select APIs in March 2026 due to energy and raw material cost inflation. A new GMP Solution Center in Wyandotte, Michigan opened in June 2025 to support biopharma and small-molecule customers. The company cites a 52% market share among originator pharmaceutical companies and serves pharmaceutical manufacturers, API manufacturers, biopharmaceutical companies, and generic drug manufacturers as primary segments. The division is supported by education and thought leadership channels including the BASF Pharma Learning Center, the "10 Billion Reasons" podcast, webinars, and LinkedIn presence.

BASF Pharma firmographics

Firmographics
Name
BASF Pharma
Legal name
BASF SE
Website
https://pharma.basf.com
Company type
Public
Founded year
1865
Operating status
Operating
Headcount range
101–250 employees
Short description
BASF Pharma Solutions, a division of BASF SE, is the world's leading manufacturer of pharmaceutical excipients and APIs (including ibuprofen and omega-3 fatty acids), serving global originator, generic, and biopharmaceutical drug manufacturers across five formulation platforms.
Ownership category
akta.pro rank

BASF Pharma industry classification

Industry
Product category
Pharmaceutical Excipients & APIs
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Pharmaceutical excipients
  • Active pharmaceutical ingredients
  • Biopharma processing aids
  • Drug formulation support
  • Pharmaceutical raw materials

Where BASF Pharma is headquartered

Location

Headquarters

HQ city
Ludwigshafen
HQ country
Germany
HQ region
Europe

Offices4 records

Markets served

BASF Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Excipients and APIs: BASF Pharma Solutions generates revenue through the sale of pharmaceutical excipients, active pharmaceutical ingredients (APIs) including ibuprofen and omega-3 fatty acids, and chemical raw materials including building blocks, reagents, protective groups, solvents, and catalysts for pharmaceutical manufacturing.
  2. Digital Services and Platform Access: Revenue is supported by digital platform services including myBASFWorld for product information, ordering, and technical support, as well as consultation and technical service support for formulation development.
  3. Contract Manufacturing and Custom Solutions: BASF provides custom pharmaceutical development and manufacturing services with regulatory, quality, and technical service support for customers globally.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProduct sales through account management

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

BASF Pharma product offering

Product offering

Core offering

BASF Pharma Solutions produces and supplies innovative pharmaceutical excipients and active pharmaceutical ingredients (APIs) including ibuprofen and omega-3 fatty acids for pharmaceutical and biopharmaceutical manufacturers worldwide. The division offers formulation expertise across five drug delivery platforms (Orals, Topicals, Parenterals, Solubilization, and Biopharma Ingredients) and supports customers with digital services including the myBASFWorld customer portal and ZoomLab virtual formulation tools.

Product overview

BASF Pharma Solutions is a comprehensive pharmaceutical portfolio comprising a wide range of excipients, APIs, and digital platforms. The core offerings include: Kolliphor® surfactants (poloxamers, HS 15, ELP) for solubilization and biologic formulations; Kollicoat® film coatings; Kollidon® (Povidone) polymers; Soluplus® for solubility enhancement; and Kollitab™ DC 87 L for tableting. BASF produces APIs including ibuprofen (with DC 85 direct compression grade) and omega-3 fatty acids. Digital services include myBASFWorld customer portal and ZoomLab® formulation tools. The portfolio serves multiple drug delivery platforms: Orals, Topicals, Parenterals, Solubilization, and Biopharma Ingredients, enabling customers to develop efficient, cost-effective, and reliable formulations across all major dosage forms.

Differentiator

Problem solved

Functional benefit

Brands

  • myBASFWorld: Digital customer portal offering centralized product details, documentation access, ordering, and shipment tracking
  • ZoomLab
  • Kollidon
  • Kollicoat
  • Kolliphor
  • Kollitab
  • Soluplus
  • SEDDS
  • SNEDDS
  • Kolliphor P 188 Bio
  • Ibuprofen DC 85
  • Kollipro

Products and services

  • Active Pharmaceutical Ingredients (APIs) World-leading portfolio of APIs manufactured at FDA-audited, cGMP-certified facilities, including ibuprofen and omega-3 fatty acids supplied to pharmaceutical manufacturers globally.
  • Ibuprofen API (including Ibuprofen DC 85) Ibuprofen API produced at the Bishop, Texas facility with four powder grades plus a direct-compressible grade (Ibuprofen DC 85) and fast-acting grades for tableting applications.
  • Kolliphor® P 188 Bio Flagship poloxamer-based surfactant used as a processing aid in biopharmaceutical manufacturing, positioned as the #1 alternative to polysorbate 20 and 80 in biologic drug formulations.
  • Kolliphor® HS 15 Non-ionic solubilizer surfactant with a documented history of safe and effective use in approved and marketed parenteral drugs and biologic formulations.
  • Kolliphor® ELP Surfactant for parenteral and solubilization applications with an established safety profile in marketed drugs.
  • Soluplus® Novel solubilization polymer for solid dispersions that increases dissolution and inhibits recrystallization of poorly soluble drug candidates.
  • Kollicoat® Film Coating Polymers Film coating product line for oral dosage forms providing immediate release, controlled release, moisture protection, and taste masking solutions.
  • Kollidon® (Povidone / PVP) PVP-based polymers originated by BASF in 1928, used as binders, solubilizers and film formers in pharmaceutical formulations.
  • Kollitab™ DC 87 L All-in-one co-processed excipient combining filler, binder, disintegrant and lubricant for direct compression tableting and continuous manufacturing processes.
  • Kollisolv® PEG Polyethylene glycol products for softgel fills, solubilization, and pharmaceutical formulations, including low-aldehyde variants for enhanced stability.
  • myBASFWorld Digital Platform Centralized customer portal providing product detail pages with technical and regulatory information, always up-to-date documentation, self-service capabilities, transparent ordering and real-time shipment tracking for pharmaceutical customers.
  • ZoomLab® Virtual laboratory service providing formulation development support for pharmaceutical customers.
  • Virtual Audit Service State-of-the-art virtual audit technology enabling authorized customers to conduct immersive 360-degree audits of the Bishop ibuprofen production facility remotely.
  • Chemical Intermediates (Building Blocks, Chiral Auxiliaries, Protective Groups, Reagents, Solvents) BASF Intermediates portfolio of over 700 chemical raw materials for synthesis in the pharmaceutical industry, marketed under the world's largest portfolio of chemical intermediates products.

Quantifiable outcome

  • Manufacturing process completed in only 4 steps versus 6-7 steps at competitors
  • +1 more outcomes

Companies that use BASF Pharma

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

BASF Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

BASF Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ACT Solutions CorpsupportingStrategic or Co-development PartnerBASF partnered with Mark Chandler of ACT Solutions Corp for a webinar on topical formulation development using self-emulsifying systems, leveraging ACT Solutions' expertise in stabilization techniques and co-processed excipients for pharmaceutical applications.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

BASF Pharma competitors and assessment

Company assessment

Direct peers

  • Avantor: Global supplier of pharma excipients, APIs, and bioprocessing ingredients to drug manufacturers and biopharma companies. Direct competitor in excipients, APIs, and biopharma raw materials with comparable distribution scale.
  • Colorcon: Specialty excipient supplier focused on film coatings, controlled-release polymers, and tableting excipients. Direct competitor to BASF's Kollicoat, Kollidon, and Kollitab product lines for oral solid dose formulations.
  • Evonik Industries: German specialty chemicals company with a dedicated Health Care business line producing pharmaceutical excipients, APIs, and drug delivery technologies. Most directly comparable peer given overlap in pharma polymers, APIs, and CDMO services for oral and parenteral formulations.
  • Ashland: Specialty chemical company producing pharmaceutical excipients, controlled-release polymers, and tablet coatings. Direct competitor in oral solid dose excipients and solubilization polymers.
  • SEPPIC (Air Liquide): Air Liquide subsidiary manufacturing specialty excipients and surfactants for pharmaceutical, cosmetic, and vaccine applications. Competes directly with BASF's Kolliphor surfactant portfolio in parenterals and biopharma.
  • International Flavors & Fragrances (IFF) Pharma Solutions: Pharmaceutical Solutions division of IFF (formerly DuPont Nutrition & Biosciences) producing pharma excipients, controlled-release polymers, and bioavailability enhancers. Direct competitor in solubilization and oral excipients.
  • JRS Pharma (J. Rettenmaier & Söhne): Specialty excipient manufacturer focused on cellulose-based binders, disintegrants, and fillers for oral solid dose formulations. Direct competitor in tableting excipients alongside BASF's Kollidon and Kollitab lines.
  • Roquette: French global leader in starch-based pharmaceutical excipients and APIs, including cyclodextrates, polyols, and biopharma excipients. Competes directly with BASF Pharma Solutions in orals, biopharma, and solubilization platforms.

Broad incumbents

  • Dow Chemical: Diversified chemical manufacturer with pharmaceutical and personal care ingredients including cellulosics, silicones, and excipients. Broader portfolio than BASF Pharma but overlaps in pharma-grade polymers and intermediates.
  • Merck KGaA (Life Science / MilliporeSigma): Life Science division of Merck KGaA offers pharmaceutical raw materials, excipients, and bioprocessing ingredients alongside a much broader lab products portfolio. Comparable in excipients and bioprocessing segments but operates across a far wider scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights5 records

Customer concentration

BASF Pharma social profiles

Digital presence

BASF Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BASF Pharma leadership team

Management profile

Number of profiles

Profiles1 record

BASF Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BASF Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BASF Pharma

What does BASF Pharma do?

BASF Pharma Solutions produces and supplies innovative pharmaceutical excipients and active pharmaceutical ingredients (APIs) including ibuprofen and omega-3 fatty acids for pharmaceutical and biopharmaceutical manufacturers worldwide. The division offers formulation expertise across five drug delivery platforms (Orals, Topicals, Parenterals, Solubilization, and Biopharma Ingredients) and supports customers with digital services including the myBASFWorld customer portal and ZoomLab virtual formulation tools.

Is BASF Pharma a public or private company?

BASF Pharma is a public company. It is classified as public and is currently operating.

When was BASF Pharma founded?

BASF Pharma was founded in 1865. It employs 101 to 250 people.

Where is BASF Pharma based?

BASF Pharma is headquartered in Ludwigshafen, Germany, in the Europe region.

How does BASF Pharma make money?

Three revenue lines are on record. Pharmaceutical Excipients and APIs are the primary driver. The others are digital Services and Platform Access and contract Manufacturing and Custom Solutions.

Who are BASF Pharma's main competitors?

Direct peers on record are Avantor, Colorcon, Evonik Industries, Ashland, SEPPIC (Air Liquide), International Flavors & Fragrances (IFF) Pharma Solutions, JRS Pharma (J. Rettenmaier & Söhne) and Roquette. Broad incumbents are Dow Chemical and Merck KGaA (Life Science / MilliporeSigma).

Does BASF Pharma have an API?

No public API is recorded for BASF Pharma.

What industry is BASF Pharma in?

BASF Pharma's product category is Pharmaceutical Excipients & APIs. Its primary akta.pro industry code is HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmTechEvolving Approaches to Taste MaskingThe article reviews evolving taste-masking technologies for oral drug products, highlighting advanced strategies such as reverse-enteric polymers, melt-granulation, and lipid encapsulation to improve patient compliance. Experts from Quotient Sciences and BASF Pharma Solutions discuss the technical challenges of masking bitter APIs in various dosage forms, including liquids and high-drug-loading solids. These developments aim to balance effective taste suppression with maintained pharmacokinetic performance and manufacturing efficiency.Endpoints NewsDrug sub­stance mak­er rais­es prices due to en­er­gy cri­sis; Spec­tron­RX gets $85MBASF Pharma Solutions raised prices for drug ingredients citing the ongoing war in the Middle East and energy crisis. The article also briefly mentions SpectronRX securing $85M and news regarding Scinai Immunotherapeutics and Cardinal Health.Cosmetics BusinessRelipidium helps to rebalance the skin’s ecosystemBASF launched Relipidium, an active ingredient that rebalances skin microbiota and boosts lipid synthesis. It increased skin hydration by 12% and beneficial Staphylococcus epidermidis by a factor of two within two weeks. BASF plans to launch more products based on its skin microbiota research platform.Cosmetics BusinessPromega and BASF develop alternative method for detecting allergenic substancesPromega and BASF developed a cell-line-based method to detect allergenic substances, replacing animal tests. The method uses a modified reporter gene to couple stress reactions to a light signal, and has been submitted to the European Commission for recognition as a standard method.CredenceresearchPharmaceutical Intermediates Market Size, Share and Forecast 2032The Pharmaceutical Intermediates market was valued at USD 37,009.08 million in 2024 and is projected to reach USD 60,372.60 million by 2032, growing at a CAGR of 6.33%, driven by rising global API production, chronic disease prevalence, and expanding generic drug pipelines. North America led the market in 2024 with a 35.35% share, followed by Asia Pacific at 29.20% and Europe at 22.38%, while key players including BASF SE, Merck KGaA, Lonza Group AG, and Aurobindo Pharma dominate through diversified portfolios and global distribution networks. The market faces challenges from raw material price volatility and stringent regulatory requirements, while opportunities lie in rising demand for high-purity, chiral, and specialty intermediates for complex drug formulations.TechadlerChiral Material Market to Witness Huge Growth by 2033The global chiral material market, valued at approximately USD 3.2 billion in 2024, is projected to grow at a compound annual growth rate of 8% through 2030, driven by pharmaceutical R&D and regulatory demands for enantiomeric purity. Key growth drivers include advancements in chiral catalysts, increased use in agrochemicals, and emerging applications in electronics, while restraints involve high production costs and regulatory challenges. Major industry players such as BASF SE, Solvay S.A., and Merck KGaA are positioned to benefit from these trends amid expanding regional demand in Asia-Pacific and North America.openPR.comPharmaceutical Chemicals Market Outlook 2025-2032: Contract Manufacturing & Specialty APIs Lead Expansion | Spectrum Chemical Mfg. Corp., BASFThe global pharmaceutical chemicals market is projected to grow from USD 147.97 billion in 2025 to USD 244.05 billion by 2032, a CAGR of 7.4%. Growth is driven by rising R&D investments, chronic disease prevalence, and biopharmaceutical demand, with Asia Pacific as a key production hub.LinkedInPharmaceutical Intermediates Market Future Trends, Challenges, Key Developments & Outlook 2033Maket Info Hubs published a market research report on May 20, 2025, projecting the global pharmaceutical intermediates market to grow from USD 60 billion in 2024 to USD 90 billion by 2033 at a CAGR of 5.5%. The analysis highlights growth drivers such as increased demand for biologics and personalized medicine, while noting challenges including high production costs and regulatory complexity. The report identifies key industry players including Lonza, Catalent, BASF, and Jubilant among others shaping the competitive landscape.Cosmetics BusinessBASF harnesses the power of chaga mushroom for new active ingredientBASF developed Inolixir, a skin-care ingredient derived from chaga mushroom via subcritical water extraction. Study participants reported it was as effective as a five-day spa trip for dark circles, fatigue lines, and dullness, and it offers anti-redness and anti-dullness benefits for sensitive skin.Cosmetics BusinessDermagenist harnesses BASF’s findings on epigenetics to revitalise fibroblastsBASF launched Dermagenist, an active ingredient that reactivates fibroblasts by inhibiting DNA methylation. The ingredient boosts collagen production, improving skin density by 18% and firmness by 15%. BASF plans to develop more epigenetic-based cosmetic ingredients.